Maxigen Biotech Revenue

About Maxigen Biotech

Maxigen Biotech Inc. (MBI) was founded in December 1998. Next year, MBI stationed in National Yang-Ming University and set up an incubation center at there to conduct the R&D work of collagen. In June,2002, Global Investment Holdings made capital investment for MBI and became one of the shareholders. In the Decemeber of same year, MBI started building its own biomedical factory office building at Wugu industrial park. Next year, MBI set up the skin care product facility in Sigang township, Tainan county. MBI utilizes its core competence in biopolymers and has developed a broad range of applications in areas such as medical devices and skincare products. MBI specializes in the developing, manufacturing, and marketing of biomedical and skincare products. Headquarters was moved to Hwa-Ya Technologypark in July, 2016. Our major shareholders include GIH Group, Mega International Commercial Bank, First Financial Holding and – NuVasive Inc., Nasdaq-listed medical device company in the US. MBI's Biomedical facility is certified by Taiwan GMP, ISO13485 and Korean KGMP. Furthermore, it passed US FDA inspection in 2009 and 2015 with no significant deviation being observed. MBI's biomedical products are mainly applied to the usage of orthopedics, aesthetic medicine, dental and ophthalmology. Production quality is in accordance with international regulations and requirements. Also our products have been certified by Taiwan, China, USA, Europe, Russia, Southeast Asia, Middle East and other emerging markets.

View contact profiles from Maxigen Biotech